Virpax Pharmaceuticals Analysis
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
Virpax Pharmaceuticals is overvalued with Real Value of 0.24 and Hype Value of 0.25. The main objective of Virpax Pharmaceuticals pink sheet analysis is to determine its intrinsic value, which is an estimate of what Virpax Pharmaceuticals is worth, separate from its market price. There are two main types of Virpax Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Virpax Pharmaceuticals pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Virpax |
Virpax Pink Sheet Analysis Notes
The company has Price to Book (P/B) ratio of 0.48. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virpax Pharmaceuticals recorded a loss per share of 71.0. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 21st of March 2025. Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.The quote for Virpax Pharmaceuticals is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call Anthony MBA at 610 727 4597 or visit https://www.virpaxpharma.com.Virpax Pharmaceuticals Investment Alerts
| Virpax Pharmaceuticals is not yet fully synchronised with the market data | |
| Virpax Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Virpax Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Virpax Pharmaceuticals currently holds about 26.06 M in cash with (16.71 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thefly.com: BofA upgrades Vir Biotechnology to Buy on underappreciated HDV opportunity VIR |
Virpax Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Virpax Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Virpax Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 831.85 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Virpax Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Virpax Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Virpax Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Virpax Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Virpax Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Virpax Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Virpax Pharmaceuticals Outstanding Bonds
Virpax Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Virpax Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Virpax bonds can be classified according to their maturity, which is the date when Virpax Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| VISA INC 365 Corp BondUS92826CAJ18 | View | |
| VISA INC 275 Corp BondUS92826CAH51 | View | |
| VISA INC 43 Corp BondUS92826CAF95 | View | |
| VISA INC 415 Corp BondUS92826CAE21 | View | |
| VISA INC 315 Corp BondUS92826CAD48 | View | |
| VISA INC Corp BondUS92826CAQ50 | View | |
| US92826CAP77 Corp BondUS92826CAP77 | View |
Virpax Pharmaceuticals Predictive Daily Indicators
Virpax Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Virpax Pharmaceuticals pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Virpax Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Virpax Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Virpax shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Virpax Pharmaceuticals. By using and applying Virpax Pink Sheet analysis, traders can create a robust methodology for identifying Virpax entry and exit points for their positions.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Virpax Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |